SBIR/STTR Research Award

Molecularly Engineered Biomaterials for Minimally Invasive Dental Treatment

Award identifier 1e922fb84cbb11ed08229e011eb85362e52614b2e71888d09f5e2c2629280feeAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$285,048

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SITEONE THERAPEUTICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
ZKBYHMUQS291
Solicitation number
PA12-088
Topic code
NIGMS

Research abstract

DESCRIPTION (provided by applicant): Synthetic modification of a natural toxin, gonyautoxin 2/3, is enabling the development of new therapies for painful neuromuscular disorders, such as anal fissure and chronic tension-type headache. Gonyautoxins target voltage-gated Na+ ion channels, a family of integral membrane proteins responsible for the transmission of signals along electrically conducting cells. Preliminary human clinical trials conducted with gonyautoxin 2/3 and a closely related compound, neosaxitoxin, indicate that these species have superior efficacy and fewer side effects than existing pharmacological treatment options for anal fissure, chronic tension-type headache, postoperative pain, and other medical conditions. Despite compelling data in gt300 human subjects, limited availability from natural sources and a low margin of safety are major obstacles to the clinical development of either species. Site One has technology in place to prepare analogues of the natural toxins by chemical synthesis from inexpensive starting materials. We have prepared ~100 modified compounds at seven position around the core structure, and have identified analogues showing an improved margin of safety and extended duration of action in in vivo models measuring local anesthesia and inhibition of muscle contraction. The overarching aim of our proposal is to evaluate a small collection of our most promising compounds, and to select a single drug candidate meeting specific safety and efficacy criteria for advancement to pre-clinical development. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Chronic tension type headache and anal fissure are debilitating medical conditions for which existing treatment options are inadequate. A family of naturally occurring molecules derived from algae has shown excellent efficacy in human clinical trials for both indications with no serious side effects, however, concerns over the low safety margin of these species have hindered development. We aim to develop a safer, more effective therapy for anal fissure and chronic tension headache by modification of these natural compounds.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

10 SBIR/STTR records share this UEI (2013–2021). Reported award amounts total $8,523,209. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.